AKT1 and breast carcinoma: Furthermore, pre-clinical studies using combined treatment with PTX and either a β-isoform-sparing PI3K inhibitor taselisib or pan-AKT inhibitor ipatasertib reduced proliferative and metastatic effects of breast cancer cells, as compared to either therapeutic strategy alone [9].